Yes, PEB SP increased so much this year, some pre Christmas funds rebalancing by the looks of it seeing values would have proportionally increased so much for PEB holdings. Upwards trend to resume once end of year rebalancing resets.
Printable View
Nah. Rebalance is just another word for a reality check. You are not going to rebalance downwards if there is a frequent string of positive announcements about adoption. In fact institutions will rebalance upwards should that be the case. Its just changing perceptions over the length of time it is going to take to attain significantly more adoption and with it significantly more lab throughput. In the absence of news there will always be a rethink of strategy driven by uncertainty.
Having said that it’s just a matter of time before increasing adoption takes place. If a medical facility like Johns Hopkins widely adopts Cxb as a clinical basis for determining whether a cystoscopy is necessary then the SP will react very positively. I would not want to be short if that announcement was made, nor if any other significant adoption announcement was made.
No news....uncertainty....cover the downside.... slow slide backwards
Indeed DK but they need more than a successful study result they need adoption on a bigger scale to support the current valuation
This came out this morning adding further " grist for the mill".
https://www.docwirenews.com/gu-oncol...ce-cystoscopy/
As a refresher, did PEB ever get that lump sum payment/reimbursement for the initial testing that was done as part of the ramp up to full approval by medicare, medicaid, and blue cross/blue shield. I think it was mentioned that there could be a reimbursement payment of something like 30 Million on lab testing of a normal invoiced value of 90+ Million. It was an optimistic view, that I've yet to find any follow up on? Would have been a nice little non dilutive cash bump.. Probably missed an announcement around this in the last 18 months of share price excitement!
No, payment not received nor was it ever very likely imo.
Cxbladder is still not covered by Bluecross or any of the US Insurers. With sleight of hand there was the announcement that United Healthcare now covered the tests but this was under its medicare policy only, not those it underwrites itself.
SP down 15% in 2 weeks, time for some good news methinks
With new funds raised @ $1.35 and the employment of more "marketing" executives to promote the advantages of Cxb, whats happened? In general no news is good news but i'm not sure this applies here.
There is definitely a reassessment of risk on asset inherent here, reflected in the slow decline of the SP
Thanks Barney. Dr Meintjes certainly has the right CV and his US commercial experience will be invaluable. I remain convinced of the high value CxBladder.
Not heard much from PEB, wondering what they are doing will all those millions, hopefully great things.
Anyone know the Q1 announcement date? Thanks
DHBs sales are never going to save this company. They have been great in trialing the tech. The only way it can succeed is to sell big overseas.
Not sure if this one has been shared before in the forum. It is a recent research paper on CXBladder Resolve.
The Diagnostic Performance of Cxbladder Resolve, Alone and in
Combination with Other Cxbladder Tests, in the Identification
and Priority Evaluation of Patients at Risk for Urothelial
Carcinoma
https://www.google.com/url?sa=t&sour...D7hCPTbP_PYtEJ